NSE / BSEHealthcare
β‚Ή1236.05-36.80-2.89%
P/E124.0Mkt Capβ‚Ή5.32 K CrEV/EBITDA89.2

Entero Healthcare Solutions Limited

P/E124.0Mkt Capβ‚Ή5.32 K CrEV/EBITDA89.2
Company Profile

Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
β€”
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 2.15% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+10.9%); Feb the lowest (-5.5%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026+7.5%Positive MonthJan 2026: +7.49%-6.0%Negative MonthFeb 2026: -6.03%+20.2%Positive MonthMar 2026: +20.24%-2.0%Negative MonthApr 2026: -2.02%+10.8%Positive MonthMay 2026: +10.83%-12.1%Negative MonthJun 2026: -12.13%+4.0%*Positive MonthJul 2026: +3.97%β€”β€”β€”β€”β€”
2025-5.5%Negative MonthJan 2025: -5.49%-5.0%Negative MonthFeb 2025: -5.05%-11.0%Negative MonthMar 2025: -10.98%+15.8%Positive MonthApr 2025: +15.82%-8.8%Negative MonthMay 2025: -8.80%-4.7%Negative MonthJun 2025: -4.65%+12.3%Positive MonthJul 2025: +12.32%-8.0%Negative MonthAug 2025: -7.96%-5.8%Negative MonthSep 2025: -5.77%-0.9%Neutral MonthOct 2025: -0.90%-3.8%Negative MonthNov 2025: -3.76%-3.5%Negative MonthDec 2025: -3.55%
2024β€”β€”-9.5%Negative MonthMar 2024: -9.54%+18.8%Positive MonthApr 2024: +18.78%-12.0%Negative MonthMay 2024: -11.96%+1.0%Neutral MonthJun 2024: +0.99%+14.9%Positive MonthJul 2024: +14.90%+14.4%Positive MonthAug 2024: +14.37%-0.1%Neutral MonthSep 2024: -0.09%+0.9%Neutral MonthOct 2024: +0.93%-1.9%Neutral MonthNov 2024: -1.88%+5.2%Positive MonthDec 2024: +5.21%
AvgΒ±SD+1.0%Β±6.5%-5.5%Β±0.5%-0.1%Β±14.4%+10.9%Β±9.2%-3.3%Β±10.1%-5.3%Β±5.4%+10.4%Β±4.7%+3.2%Β±11.2%-2.9%Β±2.8%+0.0%Β±0.9%-2.8%Β±0.9%+0.8%Β±4.4%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 3 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.205x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή409.00 Crβ–² 28.6%
EBITDA Growthβ€”
Net Profitβ‚Ή19.00 Crβ–Ό 50.0%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 33.3%
Revenue CAGR 5Y41.5%
EBITDA CAGR 5Y69.5%
Net Profit CAGR 5Y0.0%
NP Growth 1Y-50.0%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή409.00 Crβ€”β‚Ή19.00 Crβ€”β€”1.2%28.6%-50.0%
Mar 2024β‚Ή318.00 Crβ€”β‚Ή38.00 Crβ€”β€”2.3%78.7%-416.7%
Mar 2023β‚Ή178.00 Crβ€”β‚Ή-12.00β€”β€”15.0%29.9%-70.7%
Mar 2022β‚Ή137.00 Crβ€”β‚Ή-41.00β€”β€”60.3%30.5%127.8%
Mar 2021β‚Ή105.00 Crβ€”β‚Ή-18.00β€”β€”58.3%87.5%800.0%
Mar 2020β‚Ή56.00 Crβ€”β‚Ή-2.00β€”β€”15.5%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales56105137178318409336
Total Expenses73137191222353439385
EBIT / Operating Profit-17-32-54-44-34-30-49
OPM %-30%-30%-39%-25%-11%-7%-14%
Other Income21232753906757
Finance Costs125112222
Depreciation & Amortisation479109910
Profit Before Tax-2-18-41-122427-4
Tax %0%0%0%0%-58%28%-
Net Profit / PAT-2-18-41-123819-4
EPS (β‚Ή)-162.67-1,811.38-106.10-30.318.844.41-1
Dividend Payout %0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Entero Healthcare Solutions Limitedthis co.β‚Ή5.32 K Crβ‚Ή409.00 Cr124.003.1989.2028.6%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Entero Healthcare Solutions Limited and the metrics that matter.

Browse the full Equiscale Academy